The European Society of Cardiology (ESC) has released its first comprehensive clinical guidelines dedicated to the management of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Developed in collaboration with the European Renal Association, the new recommendations aim to address the dangerous, bidirectional relationship between these two conditions, which often accelerate one another and lead to premature cardiovascular events or the need for dialysis. The guidelines were formally presented at the ESC Congress 2026 and published in the European Heart Journal.
Chronic kidney disease, defined by persistent abnormalities in kidney structure or function lasting at least three months, affects an estimated 100 million people across Europe. Because the heart and kidneys are so closely linked, the ESC strategy emphasizes that clinicians must move beyond siloed treatment approaches. By integrating screening and management protocols, the new guidelines seek to identify at-risk patients earlier and deploy proven, cost-effective therapies that can slow disease progression and improve long-term patient outcomes.
The STAMP on CKD Strategy
To standardize care, the Task Force introduced the 'STAMP on CKD' framework, an acronym designed to guide healthcare providers through five essential stages: Screen, Triage, Address CKD Risk, Modify CVD management, and Plan health services. The first step, screening, mandates that every patient diagnosed with cardiovascular disease should also be tested for chronic kidney disease. This diagnostic process relies on blood creatinine levels to calculate the estimated glomerular filtration rate (eGFR) and a urine albumin-to-creatinine ratio test.
Once screening is complete, the triage phase focuses on risk stratification. Clinicians are encouraged to utilize validated risk-scoring tools that specifically incorporate kidney function metrics. This allows for a more accurate assessment of a patient's likelihood of progressing to kidney failure, while simultaneously evaluating their broader cardiovascular risk profile. By formalizing these steps, the ESC aims to ensure that no patient with underlying heart issues slips through the cracks of the diagnostic process.
Early Intervention and Pharmacological Management
Addressing risk through early, evidence-based intervention is a cornerstone of the new guidelines. The Task Force highlights the efficacy of specific drug classes, including RAS inhibitors and SGLT2 inhibitors, which, when combined with statin-based therapies, have shown significant potential in slowing the progression of chronic kidney disease and reducing the incidence of major cardiovascular events. These therapies are identified as cost-effective tools that should be introduced as soon as a patient is identified as being at risk.
However, the guidelines also provide critical nuance regarding medication safety. Because reduced kidney function can impair the body’s ability to clear certain drugs, the recommendations offer specific guidance on adjusting cardiovascular treatments for patients with CKD. This ensures that standard therapies are administered safely, preventing potential complications that could arise from improper dosing in patients with compromised renal clearance.
Multidisciplinary Care and Patient Engagement
Recognizing that the complexity of managing both heart and kidney disease often exceeds the scope of a single specialty, the guidelines advocate for active, efficient communication between cardiologists and nephrologists. Task Force Chair Professor William Herrington of the University of Oxford noted: "Active and efficient communication between specialties is often necessary due to the complexities associated with CKD. Engagement of patients and family/caregivers in the multidisciplinary care process also helps to ensure patients' priorities are met, improve their experience and promote patient-centered care."
To facilitate this, the ESC has developed a dedicated patient version of the guidelines. This resource is intended to empower individuals to better understand their condition, enabling them to participate more confidently in shared decision-making with their healthcare providers. By fostering a collaborative environment that includes the patient, the ESC hopes to improve adherence to treatment plans and overall quality of life for those living with these chronic conditions.
Future Directions and Research Needs
While the new guidelines provide a robust framework for current practice, the Task Force Chairs emphasized that significant gaps in the evidence base remain. They have called for further research to refine these protocols and address unanswered questions regarding the long-term management of patients with both CVD and CKD. The goal is to ensure that these recommendations evolve alongside new scientific discoveries, ultimately reducing the burden of these diseases on patients, healthcare systems, and society at large.
As healthcare stakeholders and policymakers begin to implement these guidelines, the focus will shift toward raising awareness and ensuring that the multidisciplinary approach becomes the standard of care. The success of this initiative will depend on the ability of medical institutions to bridge the gap between cardiology and nephrology, ensuring that patients receive timely, integrated care that addresses the full spectrum of their health needs.
